We’re pleased to welcome UCB as a partner at Frontiers Health Global Conference!
UCB was founded on January 18, 1928, by Emmanuel Janssen. It is a global biopharmaceutical company dedicated to the discovery and development of innovative drugs and solutions to transform the lives of people living with severe immunological and neurological diseases. With about 8,700 people in 40 countries, the company reported sales of 5.5 billion euros in 2022.
UCB promotes sustainable and continuous innovation through its 3 research centers in Braine-l’Alleud, Belgium; Slough, UK; and Boston, USA as well as an international network of research and development centers and several top scientific partnerships, both academic and with other biotech companies. In addition, strong clinical research partnerships have been established with other leading international biotech companies. In 2022, UCB invested 30 percent of annual sales in the R&D area.
Through UCB Ventures, UCB regularly invests in biotech startups, technology platforms, and innovative experimental therapies.
During 2022, it initiated the construction of a new, innovative, and environmentally sustainable research and development center specializing in gene therapy within its high-tech campus in Braine l’Alleud. This ongoing investment in research and innovation is intended to gain sustainable value for UCB and all its stakeholders.
Following a holistic approach, the Belgian company’s sustainability model is based on 5 pillars: Patients, People, Economy, Community, Planet. UCB’s commitment, in this sense, is to grow harmoniously, generating value in terms of: health for people with chronic diseases; well-being for those who work with the company; development for society and the communities in which it operates; and respect for the planet, containing and compensating its environmental impact as much as possible.
Through the active involvement of patients, families, caregivers, the medical-scientific community, citizens and institutions, the company strives to bring unmet needs to light daily to direct its research, while also fostering effective dialogue and collaboration on health and innovation issues.
Discover more on UCB’s approach and connect with the team at FH23.
